MX2022016367A - Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. - Google Patents
Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.Info
- Publication number
- MX2022016367A MX2022016367A MX2022016367A MX2022016367A MX2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A MX 2022016367 A MX2022016367 A MX 2022016367A
- Authority
- MX
- Mexico
- Prior art keywords
- diarrhea
- treatment
- methods
- chemotherapy
- compositions
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000037427 ion transport Effects 0.000 abstract 2
- 229920001393 Crofelemer Polymers 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010000059 abdominal discomfort Diseases 0.000 abstract 1
- 229940047615 crofelemer Drugs 0.000 abstract 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2020/038691 WO2021257089A1 (en) | 2020-06-19 | 2020-06-19 | Methods and compositions for treating chemotherapy-induced diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022016367A true MX2022016367A (es) | 2023-01-30 |
Family
ID=79268234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022016367A MX2022016367A (es) | 2020-06-19 | 2020-06-19 | Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4168027A4 (he) |
| JP (1) | JP2023538186A (he) |
| KR (1) | KR20230027226A (he) |
| AU (1) | AU2020454132A1 (he) |
| BR (1) | BR112022025741A2 (he) |
| CA (1) | CA3182864A1 (he) |
| IL (1) | IL299028A (he) |
| JO (1) | JOP20220339A1 (he) |
| MX (1) | MX2022016367A (he) |
| PH (1) | PH12022553514A1 (he) |
| WO (1) | WO2021257089A1 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115089592B (zh) * | 2022-05-21 | 2024-02-27 | 复旦大学 | 多重酪氨酸激酶在制备抑制肠道病毒71型嗜神经性病毒药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013506716A (ja) * | 2009-10-06 | 2013-02-28 | ザ レゲンツ オブ ジ ユニヴァーシティ オブ カリフォルニア | クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法 |
| PL2632550T3 (pl) * | 2010-10-31 | 2017-10-31 | Napo Pharmaceuticals Inc | Sposoby i kompozycja do leczenia biegunki związanej z HIV |
| US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
| WO2016112312A1 (en) * | 2015-01-09 | 2016-07-14 | Jaguar Animal Health | Methods of treating diarrhea in companion animals |
| WO2018106845A1 (en) * | 2016-12-06 | 2018-06-14 | Kaleido Biosciences, Inc. | Glycan polymers and related methods thereof |
| IL270984B2 (he) * | 2017-05-31 | 2026-05-01 | Napo Pharmaceuticals Inc | שיטות ותכשירים לטיפול בהפרעת שלשול מולדת |
-
2020
- 2020-06-19 IL IL299028A patent/IL299028A/he unknown
- 2020-06-19 JO JOP/2022/0339A patent/JOP20220339A1/ar unknown
- 2020-06-19 JP JP2022578560A patent/JP2023538186A/ja active Pending
- 2020-06-19 AU AU2020454132A patent/AU2020454132A1/en active Pending
- 2020-06-19 MX MX2022016367A patent/MX2022016367A/es unknown
- 2020-06-19 WO PCT/US2020/038691 patent/WO2021257089A1/en not_active Ceased
- 2020-06-19 PH PH1/2022/553514A patent/PH12022553514A1/en unknown
- 2020-06-19 EP EP20940856.6A patent/EP4168027A4/en active Pending
- 2020-06-19 KR KR1020237002209A patent/KR20230027226A/ko active Pending
- 2020-06-19 BR BR112022025741A patent/BR112022025741A2/pt unknown
- 2020-06-19 CA CA3182864A patent/CA3182864A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230027226A (ko) | 2023-02-27 |
| IL299028A (he) | 2023-02-01 |
| WO2021257089A1 (en) | 2021-12-23 |
| JOP20220339A1 (ar) | 2023-01-30 |
| PH12022553514A1 (en) | 2024-06-03 |
| CA3182864A1 (en) | 2021-12-23 |
| JP2023538186A (ja) | 2023-09-07 |
| EP4168027A4 (en) | 2024-04-03 |
| EP4168027A1 (en) | 2023-04-26 |
| BR112022025741A2 (pt) | 2023-01-03 |
| AU2020454132A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382400B (es) | Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea. | |
| ECSP13012650A (es) | Métodos y composiciones para tratar diarrea asociada con vih | |
| PY2126213A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| ECSP21080528A (es) | Compuestos antivirales que contienen nitrilo | |
| MX2024002561A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres. | |
| CL2023000847A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2023002024A (es) | Métodos de tratamiento con modulador de miosina. | |
| CL2023000943A1 (es) | Formas cristalinas de un compuesto farmacéutico. | |
| CO2024000880A2 (es) | Compuestos para el tratamiento del dolor, en particular el dolor neuropático, y/u otras enfermedades o trastornos que se asocian con at2r y/o señalización mediada por at2r | |
| MX2024012368A (es) | Terapia combinada para el tratamiento del cancer | |
| CL2024003729A1 (es) | Terapia combinada de agente activo anti-pd-1, agente activo anti-tim-3 y agente activo anti-lag-3 para tratar cáncer. | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| CL2022003634A1 (es) | Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| CL2024003535A1 (es) | Métodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia | |
| CL2023000698A1 (es) | Composiciones y metodos para el tratamiento de distrofias musculares | |
| MX2015015379A (es) | Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos. | |
| BR112022025741A2 (pt) | Usos de composições compreendendo crofelemer para tratamento de diarreia induzida por quimioterapia (cid) | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| MX2023005829A (es) | Combinaciones farmaceuticas para tratar el cancer. | |
| MX2025005720A (es) | Inhibidores de la tirosina-cinasa 2 (tyk2) | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| CO6771411A2 (es) | Metodos y composiciones para tratar diarrea asociada al vih | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos |